Hikal Ltd.

Business: Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids;

Incorporated: 1988

Chairman: Jai Hiremath

Managing Director: Jai Hiremath

Group: Kalyani

Listing: NSE: HIKAL, BSE: 524735

Headquarters: Mumbai, Maharashtra

Website: www.hikal.com

Market cap: R 1,683.67 Cr

Revenue (TTM): R 1,456.87 Cr

Earnings (TTM): R 74.20 Cr

Cash: R 31.74 Cr

Total Debt: R 660.92 Cr

Promoters' ownership: 68.77%

Liquidity: High

52 Week range: R 56.90 - 169.90

Face value: R2.00

Shares outstanding: 12,33,00,750

10 Years Aggregate:

• CFO: 1,353.39 Cr
• EBITDA: 1,891.98 Cr
• Net Profit: 551.82 Cr